ReviewEndocrine oncology (Bristol, England)2022
Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?
Review in Endocrine oncology (Bristol, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 35 citations in OpenAlex.
- Prolactinoma assessment and management: an international multidisciplinary cross-sectional survey of current practice.Pituitary · 2026Article
- Long-term endocrine outcomes of transsphenoidal surgery for prolactinomas: a 20-year single-center cohort study.Pituitary · 2026Article
- Article
- Decision-making and impulsivity in cabergoline-treated prolactinoma: findings from Iowa Gambling, Go/No-Go, and barratt scales.Pituitary · 2026Article
- The Differences Between Dopamine Agonist-Resistant and -Non-Resistant Prolactinomas: Are There Any Predictors of a Good Response?Biomedicines · 2026Article
- Long-term cabergoline use does not predict degree of prolactinoma fibrosis nor significantly impact surgical outcomes.Pituitary · 2026Article
- Dopamine agonist-associated fibrosis in prolactinomas: clinical challenges, impacts on the tumor microenvironment, and future directions.Frontiers in endocrinology · 2026Review
- Magnetic resonance imaging-based morphometric differences in the normal pituitary gland with functional and nonfunctional pituitary adenomas.Surgical neurology international · 2026Article
- Cabergoline monotherapy in GH- and PRL-cosecreting pituitary adenomas.Endocrine oncology (Bristol, England) · 2026Article
- "Just Got Diagnosed; What Worked for You?": A Mixed-Methods Analysis of Treatment Experiences in the Prolactinoma Subreddit.Journal of neurological surgery. Part B, Skull base · 2025Article
- Endoscopic endonasal transcavernous surgery for a contemporary series of 59 prolactinomas.Pituitary · 2025Article
- Predictors of favorable long-term outcomes in first-line surgery for microprolactinomas.Journal of neuro-oncology · 2025Article
- When to embark on surgery for prolactin-secreting pituitary adenoma?Annals of medicine and surgery (2012) · 2025Article
- Gender differences in prolactin thresholds and their association with lactotroph adenoma invasiveness for potential treatment considerations.Scientific reports · 2025Article
- Hormonally Active Pituitary Adenomas and Pregnancy: A Systematic Review.Medical journal of the Islamic Republic of Iran · 2025Review
- Aripiprazole use as a cause of dopamine agonist failure in the treatment of prolactinomas.Endocrine oncology (Bristol, England) · 2025Article
- MicroRNA networks in prolactinoma tumorigenesis: a scoping review.Cancer cell international · 2024Article
- Letter to the Editor Regarding "The Effect of Preoperative Cabergoline on Prolactinoma Fibrosis: A Case Series".Journal of neurological surgery reports · 2024Article
- Feasibility of Early Surgical Treatment for Adolescent Patients with Prolactinoma: A Case Report and Literature Review.Medicina (Kaunas, Lithuania) · 2024Review
- Neuro-ophthalmic evaluation and management of pituitary disease.Eye (London, England) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current treatment paradigm for prolactinomas involves dopamine agonist (DA) therapy as the first-line treatment, with surgical resection reserved for cases where there is DA failure due to resistance or intolerance. This review highlights how DA therapy can be optimised to overcome its increasingly recognised pitfalls, whilst also addressing the potential for expanding the use of surgery in the management of prolactinomas. The first part of the review discusses the limitations of DA therapy, namely: DA resistance; common DA side effects; and the rare but serious DA-induced risks of cardiac valvulopathy, impulse control disorders, psychosis, CSF rhinorrhoea and tumour fibrosis. The second part of the review explores the role of surgery in prolactinoma management with reference to its current second-line position and recent calls for surgery to be considered as an alternative first-line treatment alongside DA therapy. Randomised trials comparing medical vs surgical therapy for prolactinomas are currently underway. Pending these results, a low surgical threshold approach is herein proposed, whereby DA therapy remains the default treatment for prolactinomas unless there are specific triggers to consider surgery, including concern regarding DA side effects or risks in vulnerable patients, persistent and bothersome DA side effects, emergence of any serious risks of DA therapy, expected need for long-term DA therapy, as well as the traditional indications for surgery. This approach should optimise the use of DA therapy for those who will most benefit from it, whilst instituting surgery early in others in order to minimise the cumulative burden of prolonged DA therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.